knowledge -WSS

knowledge

author：knowledge 2025-09-27 23:31:53 - browse：7

Photograph of Glaxo Smith Kline headquarters in London for a story on multiple myeloma cancer treatment ahead of the 2024 ASCO conference — JUSTIN TALLIS/AFP via Getty Images

LONDON — The resurrection of a GSK blood cancer drug — which the company withdrew from the U.S. market not even two years ago after it failed a key study — is taking its next step forward.

At the annual American Society of Clinical Oncology conference in Chicago, researchers on Sunday are presenting trial data showing that the drug, called Blenrep, outperformed a standard therapeutic approach when combined with another medicine in patients with multiple myeloma. It’s the second positive study for Blenrep in myeloma in recent months, and next up could be a return to regulatory agencies to get the drug re-approved.

In an interview, Hesham Abdullah, GSK’s oncology research leader, said the company planned to submit Blenrep to regulators by the end of the year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Medicare explains how it will choose drugs for negotiation

WSS

BMI, flaws aside, is found to be useful estimate of body fat in youth

Change Healthcare can notify patients about the breach, HHS says

What AAP's gender

CDC advisory panel says seniors 'may' get RSV vaccine

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

What do new weight loss drugs mean for bariatric surgery?

leisure time

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

entertainment

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

How to make Best Hospitals ratings actually useful for patients

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

With trial win, GSK could get blood cancer drug back on market

Hepatitis C has a cure — but many Americans still lack access to it

Shifting the focus from loneliness to social health

ChatGPT in medicine: STAT answers readers' burning questions

How to increase colonoscopy rates? Looks like an AI can help

Jerome Adams on the need for new antivirals for Covid

Ionis drug prevents swelling attacks due to hereditary angioedema

hotspot

As pharma fights Medicare drug negotiation, hospitals, docs silent

How to increase colonoscopy rates? Looks like an AI can help

See how much Covid

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Letters to First Opinion on caregivers, digital health, and more

Complete sequence of Y chromosome published for first time

explore

entertainment

focus

focus